US drug approvals
1 approvals with a product on the US market
- Uplizna BLA761142 · approved 11 Jun 2020
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
- 0Reports naming them
- 2Markets in public records
- 0Regions & countries
- See reportsGrowth in full reports
Free public data on Viela Bio
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
See them on openFDA (opens in a new tab)
Markets where public records show them
Markets we cover where free public records show Viela Bio: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Viela Bio is in.
From our blog
Stories on the topics Viela Bio works in.
Brain Cancer Diagnosis: Imaging and New Biomarkers
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Patient Support Programmes: Helping Patients Stay on Treatment
WHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient…
Read
Alzheimer's Diagnosis: Blood Tests and Earlier Answers
57 million people live with dementia. In May 2025 the US FDA cleared the first blood test used to help…
Read